IMMX News and Press, Immix Biopharma Inc. From 12/13/22

Immix Biopharma ( NASDAQ: IMMX ) is trading ~7% higher premarket after it announced patient dosing in an ongoing Phase 1b/2a IMX-110 monotherapy clinical trial. The company expects IMX-110 clinical trial data to be released on a rolling basis beginning in Q1 2023. Once dos...

In December 2022, the 15 th patient was dosed with IMX-110 IMX-110 clinical trial data expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT scans every 8 weeks to assess tumor response to IMX-110 IMX-110 monotherapy and IMX-110 combi...

LOS ANGELES, CA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx) TM targeting oncology...

Immix Biopharma ( NASDAQ: IMMX ) on Friday said it had got an approval from an institutional review board to enroll children in its upcoming clinical trial of its IMX-110 therapy for the treatment of rhabdomyosarcoma. Rhabdomyosarcoma is a rare type of cancer that forms i...

Enrolling pediatric patients in a clinical trial is a key requirement for FDA approval of a Priority Review Voucher (“PRV”) While their future value is uncertain, PRVs are transferable to other companies and have historically sold for $67 to $350 million according to a...

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fe1f9d2e-f230-494b-9bb9-6b910a14f2aa LOS ANGELES, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, &#x...

California Soft Tissue Sarcoma Site to lead expanded clinical site consortium Historically, high-enrolling lead site has enrolled 2-3 patients per month Clinical trial data expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT sca...

Scaled-up, proprietary GMP manufacturing process to be utilized in 2 clinical trials: 2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”) 2022 planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab Clinical Trial in advanced solid tum...

Gainers: Bluejay Diagnostics BJDX +29%. DBV Technologies DBVT +12%. Arcellx (ACLX) +10%. Immix Biopharma (IMMX) +10%. AbCellera Biologics (ABCL) +8%. Losers: Precision BioSciences (DTIL) -10%. Blueprint Medicines (BPMC) -9%. Hutchmed (China) (HCM)&...

Gainers: Immix Biopharma (IMMX) +37%. Bright Green (BGXX) +29%. Repare Therapeutics (RPTX) +29%. Yumanity Therapeutics (YMTX) +24%. PDS Biotechnology (PDSB) +15%. Losers: Zosano Pharma (ZSAN) -48%. Immunic (IMUX) -41%. Aeglea BioTherapeutics (AGLE) -40%...